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p38 MAPK Activation by NGF in Primary Sensory
Neurons after Inflammation Increases TRPV1
Levels and Maintains Heat Hyperalgesia
of primary sensory neurons contributes to epinephrine-
induced peripheral sensitization (Aley et al., 2001), and
in dorsal horn neurons, to the central sensitization pro-
duced by intraplantar injection of formalin (Ji et al., 1999;
Karim et al., 2001). These actions occur with such a
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Harvard Medical School short latency (20 min) that they must be mediated
by nontranscriptional processing (Ji et al., 1999). ERKBoston, Massachusetts 02129
activation in dorsal horn neurons operating over a longer
time course (24 hr) also participates in inflammatory
pain hypersensitivity by increasing gene transcription inSummary
these cells (Ji et al., 2002).
Peripheral inflammation results in changes in neuro-Peripheral inflammation induces p38 MAPK activation
in the soma of C fiber nociceptors in the dorsal root peptide, ion channel, and receptor levels in the cell bod-
ies of DRG neurons (Noguchi et al., 1988; Woolf et al.,ganglion (DRG) after 24 hr. Inflammation also in-
creases protein, but not mRNA levels, of the heat- 1994; Ji et al., 1995; Voilley et al., 2001), but the signal
transduction pathways involved have not been identi-gated ion channel TRPV1 (VR1) in these cells, which
is then transported to peripheral but not central C fiber fied, nor is it clear what role these changes play in gener-
ating pain hypersensitivity. NGF is upregulated in in-terminals. Inhibiting p38 activation in the DRG reduces
the increase in TRPV1 in the DRG and inflamed skin flamed tissues (Woolf et al., 1994) and plays an important
role in inflammatory pain by driving peripheral sensitiza-and diminishes inflammation-induced heat hypersen-
sitivity without affecting inflammatory swelling or tion, acting directly on the peripheral terminal to pro-
duce, within a short period, heat hyperalgesia (Chuangbasal pain sensitivity. p38 activation in the DRG is
secondary to peripheral production of NGF during in- et al., 2001). However, NGF is also retrogradely trans-
ported to the cell bodies of sensory neurons in the DRG,flammation and is required for NGF-induced increases
in TRPV1. The activation of p38 in the DRG following where it increases gene expression (Lindsay and
Harmar, 1989; Woolf et al., 1994). The contribution ofretrograde NGF transport, by increasing TRPV1 levels
in nociceptor peripheral terminals in a transcription- these slower onset NGF-mediated changes in sensory
neurons to pain is unknown.independent fashion, contributes to the maintenance
of inflammatory heat hypersensitivity. The transient receptor potential ion channel TRPV1,
formerly known as vanilloid receptor-1 (VR1), which is
expressed in nociceptors, is a capsaicin- and proton-Introduction
sensitive cation-selective channel that acts as a trans-
ducer for peripheral noxious heat stimuli (Caterina et al.,Mitogen-activated protein kinases (MAPK) transduce a
broad range of extracellular stimuli into diverse intracel- 1997). The threshold of heat activation of the receptor
can be reduced by protons, repeated heat stimuli, andlular responses by producing changes in transcription
as well as by posttranslational modifications of target by PKC activation from noxious to innocuous levels
(Tominaga et al., 1998; Premkumar and Ahern, 2000).proteins (Widmann et al., 1999; Sweatt, 2001). The ERK
(extracellular signal-regulated kinase) member of the Although a null mutation of TRPV1 has minimal effects
on basal heat threshold, presumably reflecting a contri-MAPK family is activated by neuronal activity and is
involved in neuronal plasticity, including long-term po- bution of the TRP heat sensor TRPV3 (Smith et al., 2002;
Xu et al., 2002), it significantly reduces inflammatorytentiation, learning and memory, and pain hypersensitiv-
ity (Impey et al., 1999; Ji and Woolf, 2001; Sweatt, 2001). heat hyperalgesia (Caterina et al., 2000; Davis et al.,
2000), indicating a particular role for TRPV1 in inflamma-p38, a MAPK which operates through a separate intra-
cellular cascade, is activated in many cells by cellular tory pain sensitivity. We now show a slow-onset, tran-
scription-independent regulation of inflammatory heatstress and cytokines (Widmann et al., 1999). Although
an activity-dependent p38 activation occurs in neurons hypersensitivity through an increase in TRPV1 levels in
peripheral nociceptor terminals that is mediated by a(Mao et al., 1999), and p38 exerts effects in the hippo-
campus that oppose that of ERK (Bolshakov et al., 2000), NGF-induced activation of p38 in sensory neuron cell
bodies in the DRG.the contribution of p38 MAPK to neuronal function re-
mains largely unknown.
Intense noxious stimuli and tissue inflammation pro- Results
duce a pain hypersensitivity that results both from pe-
ripheral sensitization (an increased responsiveness of p38 Is Activated in DRG Neurons Following
the peripheral terminals of nociceptor primary sensory Peripheral Inflammation
neurons) and central sensitization (an increased excit- Using a phospho-specific p38 antibody, we find that
ability of dorsal horn neurons) (Woolf, 1983; Woolf and activated p38 (phospho-p38 [p-p38]) is present in only
Salter, 2000). ERK activation in the peripheral terminals 15% of DRG neurons in naive rats (Figure 1A). The p-p38
is located in the nucleus and cytoplasm of the neurons,
as well as in some surrounding nonneuronal cells. To1Correspondence: ji@helix.mgh.harvard.edu
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Figure 1. Inflammation Induces Persistent
p38 Activation in DRG Neurons
(A and B) p38 phosphorylation (p-p38) is in-
creased in DRG neurons 2 days after CFA
injection into a hindpaw. Scale bar, 50 m.
Small and large arrows indicate nonneuronal
and neuronal cells, respectively.
(C) Time course of p38 phosphorylation after
CFA administration measured by the percent-
age of p-p38 positive neurons in the DRG (n
5). *p  0.05; **p  0.01, compared to naive
control.
(D) Intensity frequency indicates an increase
in the intensity of p-p38 immunostained neu-
rons 2 days after inflammation. Three hun-
dred neurons from three animals were mea-
sured for each condition.
(E) Total p38 is expressed in many small sized
DRG neurons of naive rats. Scale bar, 50 m.
(F and G) Total p38 level is not changed 2
days after inflammation, as indicated by the
percentage of p38 positive neurons (F) and
the p38 Western band (G). ERK2, a constitu-
tively expressed protein, was used as a load-
ing control.
test if a localized peripheral inflammation activates p38 C fiber sensory neurons can be divided into two broad
groups (Snider and McMahon, 1998): NGF-responsive/in the DRG, 100 l of CFA was injected into the plantar
surface of the left hindpaw. This injection induces a TrkA-expressing neurons and GDNF-responsive/c-ret-
expressing ones. The former also express the neuropep-localized inflammation that develops over minutes, lasts
for more than a week, and is associated with swelling tides substance P and CGRP; the latter bind to lectin
IB4 and express the ATP receptor P2X3 (Averill et al.,and erythema, as well as thermal and mechanical pain
hypersensitivity (Stein et al., 1988). The inflammation 1995). We find that p-p38 heavily colocalizes with TrkA
2 days after inflammation (Figures 2D–2F). p-p38 is alsoslowly increases the percentage of p-p38 immunoreac-
tive DRG neurons (Figure 1B), reaching significance at expressed in P2X3-positive neurons (data not shown).
Moreover, p-p38 heavily colocalizes with TRPV1 (Figure24 hr, with a peak increase at 48 hr, and high levels are
maintained at 7 days (Figure 1C). The relative intensity 2G–2I), which is expressed in both types of C fibers
(Tominaga et al., 1998).of p-p38-immunoreactive neurons also increases after
the inflammation (Figure 1D). Total p38 (nonphosphory-
lated and phosphorylated) is heavily expressed in p38 Is Not Activated in Dorsal Horn Neurons
nonneuronal and small neuronal cells in the naive DRG after Peripheral Inflammation
(Figure 1E), and its levels do not increase after inflamma- Inflammation induces a sustained increase in ERK phos-
tion (Figures 1F and 1G), indicating that the increase in phorylation in second order dorsal horn neurons. This
p-p38 after inflammation is caused by increased phos- activation contributes to gene expression and mainte-
phorylation rather than elevated substrate. nance of inflammatory pain (Ji et al., 2002). However,
p38 phosphorylation is not increased in the dorsal horn
by peripheral inflammation (measured from 6 hr to 7p-p38 Is Expressed in C Fiber Sensory Neurons
days) (Figures 3A and 3B). p-p38 is, moreover, only ex-A size frequency analysis indicates that p-p38 is present
pressed in nonneuronal cells in the dorsal horn in controlmainly in small DRG neurons (cross-sectional area 
and inflamed animals, as shown by absence of colocali-600 m2 ) in both control and inflamed animals (Figure
zation with NeuN, a neuronal marker (Figures 3C and 3D).2A). Double staining of p-p38 with neurofilament-200, a
marker for myelinated A fibers, reveals almost no colo-
calization in either control or inflamed conditions, indi- p38 Activation Contributes to Inflammatory Pain
To examine if p38 activation in the DRG is involved incating that p-p38 is predominantly expressed in neurons
with unmyelinated axons, the C fibers (Figures 2B and 2C). the production of inflammatory pain hypersensitivity, we
p38 MAPK, TRPV1, and Heat Hyperalgesia
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Figure 2. p38 Is Activated in C Fiber Noci-
ceptors in the DRG after Inflammation
(A) A size frequency histogram indicates that
the cross-sectional area of the p-38 positive
neuronal profile remains similar 2 days after
inflammation even though the numbers of
such cells increase substantially. Two hun-
dred DRG neurons from each group were
measured.
(B and C) Double staining of p-p38 (red) with
neurofilament-200 (green), a marker for my-
elinated A fibers, in DRG neurons of both na-
ive (B) and 2 days inflamed (C) animals indi-
cates that p38 is predominantly activated in
unmyelinated C fiber nociceptors. Scale bar,
30 m.
(D–I) Double staining demonstrates a heavy
colocalization of p-p38 (red) with TrkA (D–F)
and TRPV1 (G–I) in DRG neurons 2 days after
inflammation. Scale bar, 30 m.
administered a specific p38 inhibitor, SB203580, into is not decreased by the p38 inhibitor (Figures 4B and
4C). This indicates that intrathecal administration ofthe intrathecal space via a catheter whose tip was posi-
tioned close to the L4 DRG in order to target p38 activity SB203580 does not alter peripheral inflammation.
To test if the p38 inhibitor has any effect on estab-in the DRG. To obtain a sustained drug infusion, the
drug was delivered by an osmotic pump (0.5 g/l/hr) lished inflammatory pain, a bolus of SB203580 (1 g)
was intrathecally administered 48 hr after the CFA injec-connected to a catheter. The catheter was implanted at
least 6 hr prior to the CFA injection. tion, at a time when the inflammatory pain is fully devel-
oped, and pain behavior was tested 0.5, 3, and 24 hrNeither heat nor mechanical basal sensitivity is af-
fected by SB203580 administration in noninflamed rats later. Posttreatment of SB203580 does not alter estab-
lished inflammatory pain at 0.5 hr after the injection but(Figures 4D and 4E). The SB203580 administration also
does not change the earliest phase of the inflammatory starts to decrease heat hyperalgesia at 3 hr and reverses
it 24 hr postinjection (Figures 4F and 4G). Mechanicalpain (6 hr) (Figures 4D and 4E). The inhibitor does, how-
ever, reduce inflammation-induced heat hyperalgesia allodynia is not altered by posttreatment with the inhibi-
tor at any time tested (Figures 4F and 4G).24 and 48 hr post CFA injection, without an effect on
mechanical allodynia (Figures 4D and 4E). Similar results
are obtained with bolus intrathecal injections (data not TRPV1 Expression Increases after Peripheral
Inflammationshown). Intrathecal SB203085 infusion does not reduce
CFA-induced inflammatory swelling, measured by paw To test if p38 mediates heat hyperglesia by regulating
TRPV1 expression, we examined TRPV1 expression inthickness (Figure 4A), and the number of ED-1-positive
inflammatory cells (macrophages) in the inflamed skin the DRG after inflammation. Previous RT-PCR studies
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Figure 3. p38 Phosphorylation in the Dorsal
Horn Is Not Increased by Inflammation
(A) Western blot analysis demonstrates that
p-p38 levels do not change in the dorsal horn
after CFA induced peripheral inflammation.
Fold represents comparative levels over con-
trol after normalizing with total p38 levels.
(B) Quantification of p-p38 levels (density of
p-p38 band) in the dorsal horn illustrates no
significant change in p-p38 levels after in-
flammation compared to control (p  0.05,
n  3).
(C and D) Double immunostaining of p-p38
and NeuN, a neuronal marker, demonstrates
a nonneuronal localization of p-p38 in the me-
dial superficial dorsal horn. p-p38 expression
remains unchanged 2 days after inflamma-
tion. Scale bar, 50 m.
do not show an increase in TRPV1 mRNA levels in the protection assay (RPA), we also find no increase in
TRPV1 mRNA levels in the DRG over the entire timeDRG after carrageenan or CFA-induced inflammation
(Tohda et al., 2001; Voilley et al., 2001). Using an RNase course studied (Figures 5A and 5B).
Figure 4. p38 Inhibition Reduces the Late
Phase of CFA-Induced Inflammatory Heat
Hyperalgesia
(A–C) Intrathecal infusion of the p38 inhibitor
SB203580 does not change the development
of inflammation of CFA-injected paws, as in-
dicated by measurement of paw thickness (A)
and number of ED-1-positive inflammatory
cells (cell number per 20 optic field) 2 days
after inflammation (C). Inflammation induces
a dramatic increase in ED-1-positive cells,
which is not affected by the p38 inhibitor (B
and C). **p  0.01, compared to control (n 
3). SB203580 (1 g/l) and control vehicle
(saline) were infused by an osmotic pump (0.5
l/hr) connected to a catheter intrathecally
implanted before CFA injection.
(D and E) Pretreatment: infusion of SB203580
as in (A) reduces the late phase of inflamma-
tory heat hyperalgesia (24 and 48 hr after CFA
injection). Mechanical allodynia is not de-
creased. Heat and mechanical sensitivity were
measured by paw withdrawal latency and paw
withdrawal threshold, respectively, and ex-
pressed as the percentage of pre-CFA baseline
measurements of vehicle control. **p  0.01,
compared to vehicle control (n  8).
(F and G) Posttreatment: intrathecal injection
of SB203580 (1 g) 48 hr post CFA produces
a delayed inhibition on inflammatory heat hy-
peralgesia. Heat and mechanical sensitivity
were tested at 0.5, 3, and 24 hr after adminis-
tration of the inhibitor. *p  0.05, compared
to vehicle (saline) control (n  8).
p38 MAPK, TRPV1, and Heat Hyperalgesia
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Figure 5. p38 Activation Mediates the Inflam-
mation-Induced Upregulation of TRPV1 in the
DRG
(A) RNase protection assay (RPA) reveals no
increase in TRPV1 mRNA levels after CFA-
induced inflammation (from 1 to 7 days). Fold
represents comparative levels over control
after normalizing with an actin control.
(B) Quantification of RPA results shows no
significant change in TRPV1 mRNA levels
after inflammation compared to control (n 
3, p  0.05).
(C) The high TRPV1-immunoreactive band
around 140 kDa detected by Western blot
shifts to a low band of 90 kDa after treat-
ment of DRG lysate with N-glycosidase F (500
unit for 50 g) at 37C for 1 hr, indicating
that the high band is a glycosylated form of
TRPV1.
(D) A similar high band is also detected in
the spinal cord of wild-type mice, but not of
TRPV1-deficient mice.
(E) The GSK TRPV1 antibody shows strong
labeling in the superficial dorsal horn of wild-
type mice, but no specific staining is found
in the spinal cord of TRPV1-deficient mice.
Scale 50 m.
(F) Western blot analysis indicates a persis-
tent increase in TRPV1 protein levels after
inflammation. This upregulation at 2 days is
blocked by intrathecal injection of SB203580
(1 g, twice a day for 2 days). Fold represents
comparative levels over control after nor-
malizing with a loading control.
(G) Quantification of TRPV1 levels, as shown
in (F). **p  0.01, compared to control; p 
0.05, compared to CFA, n  5.
(H) Immunohistochemistry confirms an in-
crease in TRPV1 levels 2 days after inflamma-
tion, which is decreased by SB203580 deliv-
ered via osmotic pump. Scale bar, 50 m.
(I) Quantification of TRPV1 levels by the per-
centage of TRPV1-positive neurons as dem-
onstrated in (G). **p 0.01, compared to con-
trol; p  0.01, compared to CFA, n  5.
Using an antibody raised against the C-terminal of the Peripheral inflammation induces a sustained increase
in TRPV1 protein levels in the DRG, as detected byTRPV1 receptor (obtained from C. Parsons, Glaxo Smith
Kline), Western blot analysis reveals a band around 140 Western blots using the GSK anti-TRPV1 antibody (Fig-
ure 5F). Consistent with these results, immunohisto-kDa in samples obtained from DRG, spinal cord, sciatic
nerve, and hindpaw skin. This antibody also recognizes chemistry also demonstrates an increase in the number
of TRPV1 immunoreactive neurons in the DRG 2 daysa low band around 90 kDa in DRG samples. After incuba-
tion of DRG lysate with N-glycosidase F, the high band after inflammation (Figure 5H). Identical immunostaining
results were obtained using a different TRPV1 antibodyshifts to the low band (Figure 5C), indicating that the
high band is a glycosylated form of TRPV1, as reported (produced by D. Julius and M. Caterina). In the contralat-
eral L4, L5 DRGs, we did not find changes of levels ofbefore (Kedei et al., 2001; Yiangou et al., 2001). The high
band is abolished after preabsorption of the antibody TRPV1 (97% of naive control, n  2) or p-p38 (98% of
naive control, n  2) 2 days after inflammation.with blocking peptide at 1 M. Western blot analysis
with this antibody shows a similar high band (140 kDa)
in wild-type but not in TRPV1 knockout mice (Figure p38 Activation and TRPV1 Expression
SB203580 (1 g) administered intrathecally twice a day5D). Immunohistochemistry using this TRPV1 antibody
reveals dense staining in the superficial dorsal horn of for 2 days, with the first injection given 30 min prior to
CFA injection, decreases inflammatory heat hyperalge-wild-type mice, but no staining in the spinal cord of
TRPV1 knockout mice (Figure 5E). sia as effectively as osmotic pump administration of the
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Figure 6. p38 Activation Mediates the Inflammation-Induced Upregulation of TRPV1 in the Sciatic Nerve and Hindpaw Skin
(A–C) Inflammation does not induce a distinct change in TRPV1 levels in the spinal dorsal horn, as shown by TRPV1 immunostaining (A and
B) and Western blot (C).
(D–G) Inflammation induces an increase in TRPV1-labeled nerve fibers in the sciatic nerve (D and E) and hindpaw skin (F and G). TRPV1
labeling is found only in nerve fibers in the epidermis and dermis of inflamed hindpaw skin. Large and small arrows indicate nerve bundle
and thin fibers, respectively. Scales bars, 50 m.
(H and J) Western blot analysis indicates an increase in TRPV1 levels in the sciatic nerve (H) and hindpaw skin (J). Both increases are blocked
by intrathecal injection of SB203580 (1 g, twice a day for 2 days). Fold represents comparative levels over control after normalizing with a
loading control.
(I and K) Quantification of TRPV1 levels in the sciatic nerve (I) and hindpaw skin (K). **p  0.01, compared to control; p  0.01, compared
to CFA, n  3 for control and CFA; n  4 for SB (SB203580). In all the cases, animals were inflamed with CFA for 2 days.
drug (data not shown). This treatment also blocks the labeled fibers are barely detectable in control hindpaw
skin, but many nerve bundles and single nerve fibersCFA-induced upregulation of TRPV1 protein at 2 days
(Figures 5F and 5G). SB203580 also decreases the in- are found in the inflamed dermis and epidermis (Figures
6F and 6G). No nonneuronal TRPV1-labeled cells werecrease in the number of TRPV1-immunoreactive neu-
rons after inflammation (Figures 5H and 5I). identified. The inflammation-induced TRPV1 increase
in the sciatic nerve and hindpaw skin is prevented byTRPV1 is anterogradely transported from the DRG,
along the sciatic nerve, to peripheral nerve terminals in intrathecal injection of SB203580 (1 g, twice a day for
2 days, with the first injection given 30 min prior to CFAthe skin, and via the dorsal root to central terminals in
the spinal cord dorsal horn (Guo et al., 1999). Two days injection) (Figures 6H–6K).
after inflammation, TRPV1 protein levels in the dorsal
horn do not change significantly (115%  30% of the NGF, p38 Activation, and TRPV1 Expression
p38 is activated in TrkA-expressing DRG neurons (Fig-control, p  0.05, n  4, Western blot analysis) (Figures
6A–6C). In contrast, inflammation produces an increase ure 2). NGF levels increase in inflamed tissues, and this
neurotrophin plays an important role in generating in-in TRPV1 protein levels in the sciatic nerve (2.8- to 4.3-
fold increase) and an even greater increase in the skin flammatory hyperalgesia (Woolf et al., 1994). To test if
NGF has a role in p38 activation, NGF antiserum (5 l/g(17.7- to 25-fold increase) (Figures 6D–6K). TRPV1-
p38 MAPK, TRPV1, and Heat Hyperalgesia
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Figure 7. NGF Is Required for p38 Activation
and VR1 Upregulation after Inflammation
(A) NGF antiserum treatment (5 l/g body
weight, 84 mg/ml i.p., once a day for 2 days)
suppresses the inflammation-induced in-
crease in p-p38 and TRPV1 levels in the DRG
2 days after CFA injection.
(B) This treatment also alleviates inflamma-
tory pain, especially heat hyperalgesia. Heat
and mechanical sensitivity were measured by
paw withdrawal latency and paw withdrawal
threshold, respectively, and expressed as a
percentage of pre-CFA baseline measure-
ments of control serum. *p  0.05, compared
to CFA, n  3.
body weight, 84 mg/ml, i.p.) was injected once a day antiinflammatory role, since NGF appears to regulate
the immune response (Stanisz and Stanisz, 2000).for 2 days, with the first injection 1 hr prior to CFA
injection, to neutralize NGF (Woolf et al., 1994). This Intrathecal administration of NGF at two doses, 1 or
2 g, twice a day for 3 days increases TRPV1 proteintreatment decreases the activation of p38 by CFA, the
inflammation-induced upregulation of TRPV1 (Figure levels in a dose-dependent way (Figure 8B) without af-
fecting TRPV1 mRNA levels (Figure 8A). Immunohisto-7A), and inflammatory heat hyperalgesia (Figure 7B). In
agreement with previous studies (Woolf et al., 1994; chemical analysis also demonstrates an increase in
p-p38 and TRPV1 levels in DRG neurons following theSammons et al., 2000), we did not observe any detect-
able effect of the neutralizing NGF antibody on the CFA- intrathecal NGF administration (Figures 8C and 8D).
SB203580 (1 g) coadministrated with the NGF (twiceinduced edema or erythema of the inflamed hind paw.
We cannot exclude that NGF may have some subtle a day for 3 days) significantly suppresses the NGF-
Figure 8. NGF Induces TRPV1 Upregulation
in the DRG via p38 Activation Both In Vivo
and in DRG Cultures
(A) RNase protection assay reveals no in-
crease in TRPV1 mRNA levels after intrathe-
cal injection of NGF at 1 and 2 g, twice a
day for 3 days. Fold represents comparative
levels over control after normalizing with an
actin control.
(B) Western blot analysis indicates an in-
creased dose-dependent expression of
TRPV1 protein levels after intrathecal NGF.
Fold represents comparative levels over con-
trol after normalizing with a loading control.
(C and D) Immunohistochemistry indicates in-
creased p-p38 and TRPV1 expression after
intrathecal injection of NGF (2 g, twice a day
for 3 days). **p  0.01, compared to control
(saline), n  3. Scale bar, 50 m.
(E) The NGF-induced increase in TRPV1 lev-
els is blocked by the p38 inhibitor SB203580
(1 g) coadministered with NGF for 3 days.
**p  0.01, compared to vehicle (saline);
p  0.01, compared to NGF, n  3.
(F) Immunocytochemistry illustrates an in-
crease in TRPV1 levels 2 days after NGF (100
ng/ml) treatment of adult DRG neuronal cul-
tures. The increase is reversed by cotreat-
ment of SB203580 (20 M). Scale bar, 50 m.
(G) Quantification of intensity of TRPV1-
labled neurons, as shown in (F). **p  0.01,
compared to control; p  0.01, compared
to CFA, n  3.
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Figure 9. Schematic Representation of the
Involvement of p38 in Heat Hyperalgesia after
Peripheral Inflammation
In the absence of peripheral inflammation,
TRPV1 is synthesized in the cell bodies of
primary sensory neurons in the DRG and
transported both to peripheral and central
terminals, contributing to heat sensitivity in
the periphery. After inflammation, NGF is pro-
duced in inflamed tissue, taken up by periph-
eral nerve terminals, and retrogradely trans-
ported to the cell body in the DRG. NGF in
the cell body activates p38, which in turn in-
creases TRPV1 translation. Increased TRPV1
is anterogradely transported to peripheral
terminals, increasing heat sensitivity.
induced TRPV1 increase, as indicated both by the per- most of which are nociceptors (Snider and McMahon,
1998). This indicates that p38 activation in DRG neuronscentage of TRPV1-labeled neurons (Figure 8E) as well
is not a universal response of neurons to stress, activity,as the intensity of TRPV1-positive neurons (data not
or inflammation but is a restricted change induced byshown).
a specific signal in a particular subset of neurons. TheNGF regulates capsaicin sensitivity and TRPV1 ex-
effects of p38 activation are limited, moreover, to heatpression in cultured DRG neurons (Nicholas et al., 1999;
hyperalgesia, with no effect on mechanical hypersensi-Winter et al., 1988; Winston et al., 2001). We used adult
tivity, a finding in keeping with a pivotal role for TRPV1primary DRG neuron culture, therefore, as an indepen-
as a downstream target for activation of p38. The eleva-dent system to study p38-mediated TRPV1 regulation.
tion in TRPV1 expression in the cell body is accompa-NGF administration (100 ng/ml) for 2 days increases
nied by an increase in TRPV1 in the peripheral but notTRPV1 levels in cultured DRG neurons, and these levels
the central terminals of the C fibers, implying a directedare decreased by SB203580 (20 M) (Figures 8F and 8G).
trafficking of the receptor to the peripheral axon after
inflammation.
Discussion p38 has several proinflammatory roles (Badger et al.,
1996), and systemically administered p38 inhibitors pro-
ERK members of the MAPK family act both in the noci- duce antiinflammatory effects by reducing the synthesis
ceptor peripheral terminal and the dorsal horn to pro- of the cytokines TNF-	 and IL-1
, as well as Cox-2
duce pain hypersensitivity within 20 min of their activa- induction in inflammatory cells (Lee et al., 1994; Paul et
tion by epinephrine and nociceptive synaptic input, al., 1999; Widmann et al., 1999). Reducing Cox-2 will
respectively, an effect that is likely due to posttransla- decrease prostaglandin production, a major inflamma-
tional processing (Ji et al., 1999; Aley et al., 2001; Karim tory mediator that generates peripheral sensitization by
et al., 2001). Persistent ERK activation in the dorsal horn potentiating voltage-gated sodium channels in nocicep-
induced by peripheral inflammation also contributes to tor peripheral terminals (Julius and Basbaum, 2001;
transcriptional regulation of dynorphin in superficial dor- Woolf and Salter, 2000). The present study indicates an
sal horn neurons (Ji et al., 2002). We now describe yet additional role for p38 in inflammation, one that acts in
another influence of MAP kinases on pain, one mediated DRG neurons to regulate TRPV1 expression and thereby
by p38 and not by ERK, with a slow onset, and which heat hyperalgesia. Intrathecal administration of a p38
acts not in the nociceptor terminal or dorsal horn, but inhibitor targeted to reach DRG neurons innervating the
in the cell bodies of sensory neurons in the DRG. The inflamed tissue blocks this action without reducing the
p38 activation in the DRG is initiated by retrograde trans- local inflammation. The intrathecal route can be used
port of NGF released from inflamed tissue and acts to to deliver molecules directly to DRG neurons including
increase translation and transport of TRPV1 to the pe- NGF because the dural membrane extends onto the
ripheral nociceptor terminal, where it contributes to the capsule of the DRG so that the proximal face of the
maintenance of inflammatory heat pain hypersensitivity DRG is in direct continuity with the subarachnoid space
(Figure 9). (Michael et al., 1997; Porreca et al., 1999). Since p38 is
Peripheral inflammation does not increase p38 activa- not activated in the spinal cord (Figure 3), any effects
tion in large, low threshold A fibers or in dorsal horn of a p38 inhibitor when administered intrathecally will
be limited to the DRG.neurons; the effect is restricted to small DRG neurons,
p38 MAPK, TRPV1, and Heat Hyperalgesia
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Neuronal activity has been implicated in the activation either directly or through PKC to sensitize the receptor
of p38 in cerebellar neurons (Mao et al., 1999). However, (Premkumar and Ahern, 2000; Tominaga et al., 1998;
it is unlikely that afferent activity initiated in the periphery Zygmunt et al., 1999). p38 alters heat transduction by
by the release of local inflammatory mediators plays a changing the number of heat transducers in the terminal,
major role in p38 activation in the DRG, because no rather than their sensitivity, a novel form of regulation.
activation was detected for up to 6 hr after the CFA Previous studies have reported increased TRPV1 immu-
injection, even though the tissue is inflamed and both noreactive nerve terminals after inflammation (Carlton
thermal and mechanical hypersensitivity are fully ex- and Coggeshall, 2001; Yiangou et al., 2001). NGF and
pressed at this time. The suppressant effect of NGF inflammation also increase the sensitivity of DRG neu-
antiserum on the inflammation-induced activation of p38 rons to capsaicin (Nicholas et al., 1999; Winter et al.,
and the opposite effect produced by intrathecal NGF 1988), an effect that is likely to reflect increased TRPV1
administration clearly suggest a role for NGF in the acti- translation. Our data show a 20-fold increase of TRPV1
vation of p38 in the DRG. The delay in p38 activation in inflamed hindpaw skin, with a relatively lower increase
after inflammation closely matches the time required for in the DRG. The redistribution of TRPV1 out of the DRG
the retrograde transport of NGF from the inflamed paw and toward the periphery resembles the alterations re-
to the DRG (Miller and Kaplan, 2001), and NGF induces ported for the sodium channel Nav 1.8 after peripheral
a sustained activation of p38 in PC 12 cells (Morooka and nerve injury (Novakovic et al., 1998). The very small in-
Nishida, 1998). The mechanisms by which NGF might crease in TRPV1 in the dorsal horn, where the central
trigger p38 activation remain to be established. One terminals of C fibers are located, seems to indicate a
possibility is that NGF regulates p38 via the Ras/Rho directed transport down peripheral axons after inflam-
cascade. The Rho family of guanine nucleotide binding mation. The BNAC1	 sodium channel is only transported
proteins, including Rho, Rac1, and Cdc42, regulate the down the peripheral axons of DRG neurons (Garcia-
activation of p38 kinase (Coso et al., 1995; Xing et al., Anoveros et al., 2001), so some sorting mechanism must
1998). However, not all neurons that are labeled with be present at the axon branch point in the DRG to
p-p38 express TrkA, so NGF is unlikely to be the only achieve such directed traffic.
peripheral signal responsible for p38 activation in DRG Inflammatory heat hyperalgesia involves both acute
neurons. changes resulting from posttranslational modifications
Inflammation increases transcription of several genes of existing TRPV1 in nociceptor peripheral terminals, as
in DRG neurons, including the neuropeptides substance well as more delayed changes resulting from increased
P and CGRP (Noguchi et al., 1988), the neurotrophin transport of TRPV1 from the cell body to the peripheral
BDNF (Mannion et al., 1998), the growth promoting pro- terminal. The latter is the consequence of a NGF-medi-
tein GAP-43 (Leslie et al., 1995), and the ion channels ated activation of p38 in the DRG cell body after retro-
NaV1.8 (SNS) (Tanaka et al., 1998) and ASIC (Voilley et grade transport of NGF from the periphery to the cell
al., 2001). NGF is a major factor in regulating gene tran- body. The role of p38 in increasing translation and trans-
scription after inflammation (Lindsay and Harmar, 1989; port of the TRPV1 ion channel without changing its tran-
Leslie et al., 1995; Mannion et al., 1998), and p38 may scription represents a novel form of regulation of sen-
underlie the transcriptional regulation of these genes. sory neuronal function, one that would not be detected
Interestingly, TRPV1 differs from many other molecules by transcription profiling techniques such as high den-
in the DRG, which show parallel changes in their mRNA sity oligonucleotide microarrays.
and protein levels (Hokfelt et al., 1994). In agreement
with several previous studies (Sanchez et al., 2001; Experimental Procedures
Tohda et al., 2001; Voilley et al., 2001), we did not detect
Animalsany increase in TRPV1 mRNA levels in the DRG after
Adult male Sprague-Dawley rats (240–320 g) were used accordinginduction of peripheral inflammation (Figures 5A and
to Massachusetts General Hospital Animal Care institutional guide-5B). Neither did we find an increase in TRPV1 mRNA
lines. All procedures were performed under pentobarbital anesthe-after intrathecal NGF treatment (Figure 8A). However,
sia (50 mg/kg, i.p.). Complete Freund’s adjuvant (CFA, 100 l) was
both inflammation and NGF increased the expression injected into the plantar surface of the left hindpaw. For intrathecal
of TRPV1 protein levels in the DRG (Figures 5F and drug delivery, a PE10 catheter was implanted into the intrathecal
8B). p38 can potentially regulate protein expression in space of the spinal cord at the L4 DRG level, and 10l of p38 inhibitor
SB203580 (1 g; Calbiochem) was administered. For sustained drugseveral different ways, activating transcription factors
delivery, an Alzet osmotic pump (7 day pump, 0.5 l/hr) was filledsuch as ATF-2, ELK-1, and CREB to increase transcrip-
with the p38 inhibitor SB203580 (1 g/l) in saline, and the associ-tion (Xing et al., 1998; Widmann et al., 1999; Ji and
ated catheter implanted intrathecally at least 6 hr before CFA injec-Woolf., 2001), increasing mRNA stability (Faour et al.,
tion. Saline was used as vehicle control for the osmotic pump. NGF
2001) or increasing translation. One major target of p38 antiserum (Woolf et al., 1994) was injected daily for 2 days (i.p., 84
is the translational factor eIF4E, the phosphorylation of mg/ml, 5 l/gram body weight), with the first injection 1 hr before
which results in increased affinity of eIF4E for capped CFA injection. NGF (1 or 2 g in 10 l; Boeringer) was intrathecally
injected twice a day for 3 days. NGF and SB203580 were coadminis-RNA (Gingras et al., 1999; Raught and Gingras, 1999).
tered in some animals.Both ERK and p38 MAPK phosphorylate eIF4E via
Mnk1/2 (MAPK-interacting kinase 1 and 2) (Wang et al.,
Immunohistochemistry1998; Waskiewicz et al., 1997) and in this way could
Rats were perfused through the ascending aorta with saline followed
increase translation. by 4% paraformaldehyde with 1.5% picric acid. L4 and L5 DRGs,
The sensitivity of TRPV1 in the peripheral terminal is L4-L5 spinal cord segments, sciatic nerves, and plantar surface of
controlled by many factors, including protons, endocan- hindpaw skin were dissected. For mice tissue, fresh DRGs and spinal
cords were dissected and fixed in the same fixative for 3 hr. DRGnabinoids, as well as NGF and bradykinin, which act
Neuron
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and transverse spinal cord sections (15m) were cut and processed sured with a set of von Frey hairs. The threshold was taken as the
lowest force that repetitively evoked a brisk withdrawal response.for immunohistochemistry using the ABC method (Ji et al., 1995).
The following antibodies were used: polyclonal anti-p38 and phos- Thermal paw withdrawal latency was measured using the Har-
greaves radiant heat apparatus and averaged over three trials.pho-p38 (1:300; New England BioLabs), and polyclonal anti-VR1
(1:5000; provided by GSK and Dr. David Julius). Immunofluores-
cence was performed for double staining for phospho-p38 (anti- Quantification and Statistics
rabbit, 1:300) with VR1 (anti-guinea pig, 1:3000; Neuromics), P2X3 The images of immunostained DRG sections were captured with a
(anti-guinea pig, 1:3000; Neuromics), or NeuN (anti-mouse, 1:5000; CCD camera, and the intensity was measured (IP lab software) and
Chemicon), and for single staining for ED-1 (anti-mouse, 1:5000; number of immunoreactive neuronal profiles was counted in a
Serotec). In brief, DRG and spinal sections were incubated with a blinded fashion. Control and treated DRG sections were mounted
mixture of two primary antibodies overnight at 4C and followed on the same slides and processed under the same conditions. Every
by a mixture of FITC- and CY3-congugated secondary antibodies fifth section was picked from a series of consecutive DRG sections
(1:300; Jackson Immunolabs) for 2 hr at room temperature (RT) (Ji (20 m), and four sections were counted for each DRG and ex-
et al., 2002). The sciatic nerve sections (10 m) and skin sections pressed as the percentage of total neuronal profiles (Ji et al., 1996).
(40 m) were processed for immunofluorescence using the GSK For cell counting in the skin, four sections were randomly selected
VR1 antibody. The Tyramide Signal Amplification (TSA; NEN) kit from each rat, and labeled cells in a 20 optic field on each section
was used to perform double staining with two polyclonal rabbit were counted. For Western blot and RNase protection assay, the
antibodies (phospho p38 and TrkA) (Amaya et al., 2000). films were scanned, and the density of specific bands was measured
and normalized with an internal loading control band. Data are repre-
Western Blot sented as mean  SEM. Differences between groups were com-
The L4 and L5 DRGs and dorsal horns (lumbar enlargement) were pared using Student’s t test or ANOVA, followed by Fisher’s PLSD.
homogenized in a buffer containing a cocktail of proteinase and For nonparametric data, the Mann-Whittney U test was applied. The
phosphatase inhibitors. The sciatic nerves and hindpaw skins were criterion for statistical significance was p  0.05.
homogenized by polytron in the same buffer. Protein samples were
separated on a SDS-PAGE gradient gel (4%–15%; Bio-Rad) and Acknowledgments
transferred to PVDF filters. The blots were blocked with 5% milk for
1 hr and incubated with phospho-p38 antibody (1:1000) or VR1 This work was supported by NIH RO1 NS40698 (R.R.J.) and RO1
antibody (1:1000) overnight at 4C. The blots were then incubated NS39518 (C.J.W.). We thank Drs. David Julius and Michael Caterina
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(superfilm; Amersham) for 2–30 min. The blots were then incubated Plumpton (Glaxo Smith Kline, UK) for a TRPV1 antibody, and Dr. L.
in stripping buffer (100 M 2-mercaptoethanol, 2% SDS, 62.5 mM Reichardt (UCSF) for a TrkA antibody.
Tris [pH 6.7]) at 50C for 30 min and reprobed with p38 and ERK2
antibody (1:3000; New England Biolabs) as loading control. For the
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Biolabs) at 37C for 1 hr, followed by VR1 Western blot.
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